DK2044199T3 - Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi - Google Patents

Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi

Info

Publication number
DK2044199T3
DK2044199T3 DK07810511.1T DK07810511T DK2044199T3 DK 2044199 T3 DK2044199 T3 DK 2044199T3 DK 07810511 T DK07810511 T DK 07810511T DK 2044199 T3 DK2044199 T3 DK 2044199T3
Authority
DK
Denmark
Prior art keywords
serca2a
anterograde
adeno
extended
gene therapy
Prior art date
Application number
DK07810511.1T
Other languages
English (en)
Inventor
Krisztina Maria Zsebo
Original Assignee
Celladon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celladon Corp filed Critical Celladon Corp
Application granted granted Critical
Publication of DK2044199T3 publication Critical patent/DK2044199T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DK07810511.1T 2006-07-25 2007-07-16 Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi DK2044199T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83332406P 2006-07-25 2006-07-25
PCT/US2007/016129 WO2008013692A2 (en) 2006-07-25 2007-07-16 Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy

Publications (1)

Publication Number Publication Date
DK2044199T3 true DK2044199T3 (da) 2013-02-11

Family

ID=38581949

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07810511.1T DK2044199T3 (da) 2006-07-25 2007-07-16 Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi

Country Status (13)

Country Link
US (2) US20080076730A1 (da)
EP (2) EP2460879A1 (da)
JP (2) JP5623740B2 (da)
KR (1) KR20090035711A (da)
CN (1) CN101495627A (da)
AU (1) AU2007277392A1 (da)
CA (1) CA2658628A1 (da)
DK (1) DK2044199T3 (da)
ES (1) ES2398593T3 (da)
GB (1) GB2437893A (da)
IL (1) IL196541A (da)
PL (1) PL2044199T3 (da)
WO (1) WO2008013692A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100129295A (ko) * 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물
PH12012501579A1 (en) * 2010-01-05 2012-10-22 Michael Aaron Vertical axis variable geometry wind energy collection system
WO2017184613A1 (en) * 2016-04-18 2017-10-26 Eiger Biopharmaceuticals, Inc. Methods and compositions for consistent intracoronary administration of a biologic
JP2020516291A (ja) * 2017-04-14 2020-06-11 レジェンクスバイオ インコーポレーテッド ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸−２−スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5587308A (en) * 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6268213B1 (en) * 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6613749B1 (en) 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US5773289A (en) * 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE69608122T3 (de) 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie
US20020001574A1 (en) 1995-12-13 2002-01-03 Jon A. Woiff Process of delivering a polynucleotide to a muscle cell via the vascular system
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US20090239940A1 (en) * 1997-07-22 2009-09-24 Del Monte Federica Treating heart failure and ventricular arrhythmias
US20050095227A1 (en) * 1997-07-22 2005-05-05 The General Hospital Corporation Treating heart failure
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6410300B1 (en) * 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
CN101186928A (zh) * 1998-02-11 2008-05-28 加利福尼亚大学董事会 核酸和血管活性剂相组合用于加强的基因投递
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
AU763049B2 (en) * 1998-12-28 2003-07-10 Arch Development Corporation Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
CA2389524A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CA2373110A1 (en) * 2000-03-14 2001-09-20 Neurologix, Inc. Production of chimeric capsid vectors
US20020106381A1 (en) * 2000-06-13 2002-08-08 High Katherine A. Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
EP1324780A4 (en) * 2000-09-06 2005-06-22 Univ Johns Hopkins METHODS OF TREATING CARDIAC ARRHYTHMIA
EP1317289B1 (en) * 2000-09-11 2009-02-25 The Regents of the University of California Dominant negative PLB mutant for use in treating cardiac disease
NZ532635A (en) * 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
ES2286644T3 (es) * 2003-07-17 2007-12-01 Bayerische Julius-Maximilians-Universitat Wurzburg Compuestos destinados al tratamiento de enfermedades coronarias y/o vasculares perifericas.
WO2005023292A1 (en) * 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
EP1691609A4 (en) * 2003-12-11 2006-11-29 Mirus Bio Corp RELEASE OF VIRUS VECTORS ANEXTRAVASAL PARENCHYM CELLS
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
CN101056539B (zh) * 2004-09-09 2012-12-12 综合医院公司 调节心脏细胞中的磷酸酶活性
WO2006089340A2 (en) * 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
KR20100129295A (ko) * 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물

Also Published As

Publication number Publication date
GB0716413D0 (en) 2007-10-03
IL196541A0 (en) 2009-11-18
EP2044199B1 (en) 2012-11-14
KR20090035711A (ko) 2009-04-10
CA2658628A1 (en) 2008-01-31
EP2460879A1 (en) 2012-06-06
ES2398593T3 (es) 2013-03-20
JP2009544698A (ja) 2009-12-17
AU2007277392A1 (en) 2008-01-31
US20170252462A1 (en) 2017-09-07
EP2044199A2 (en) 2009-04-08
JP5623740B2 (ja) 2014-11-12
GB2437893A (en) 2007-11-07
CN101495627A (zh) 2009-07-29
WO2008013692A2 (en) 2008-01-31
US20080076730A1 (en) 2008-03-27
JP2014218509A (ja) 2014-11-20
WO2008013692A3 (en) 2008-05-02
IL196541A (en) 2012-12-31
PL2044199T3 (pl) 2013-04-30

Similar Documents

Publication Publication Date Title
FIC20230026I1 (fi) Etranakogeenidetsaparvoveekki (adenoassosioitu virusvektori, joka sisältää ihmisen hyytymistekijä IX:n geenin koodonioptimoitua Padua-johdannaista B-hemofilian hoitoon)
DK2527471T3 (da) Diagnosticering af cancer ved anvendelse af genomsekvensering
DE602007000323D1 (de) Abgabe von therapeutischen Vorrichtungen
HUE061060T2 (hu) Replikáció-defektív arenavírus vektorok
DE602007000091D1 (de) Radialventilator
EP2076162A4 (en) DISHWASHER WITH ADJUSTABLE BASKET / ADJUSTABLE BASKETS
EP2198016A4 (en) ADENO ASSOCIATED SWINE VIRUS
EP1766235A4 (en) CENTRIFUGAL PUMP
DK2054428T3 (da) Udvikling af bestanddele til denque-virus-vaccine
EP2131390A4 (en) PLASMA PROCESSOR
HUE047767T2 (hu) Macitentánt tartalmazó terápiás készítmények
EP2176420A4 (en) DERIVED FROM VIRUS ANTIMICROBIAL PEPTIDES
EP2349415A4 (en) CANNULA HOUSING FOR SIMPLE MEDICINAL INJECTION
BRPI0811016A2 (pt) Proteína li truncada do papiloma vírus humano tipo 16
DK2222315T3 (da) Stabiliserede faktor-ix-formuleringer indeholdende trehalose
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK2044199T3 (da) Forlænget anterograd epicardial koronar-infusion af adeno-associerede virusvektorer omfattende SERCA2A til genterapi
DE602005027253D1 (de) Herbizidresistenz verleihende gene
EP1955719A4 (en) OPPOSITION AGAINST INFECTIONS WITH FLUTING VIRUS
DK2178903T3 (da) Optimeret denguevirus-adgangsinhiberede peptid (DN81)
EP1786904A4 (en) Adenovirus vector COMPOSITIONS
DE602008005536D1 (de) Herstellung von MnB12H12
EP1978260A4 (en) ZENTRIFUGALABFLUSSPUMPE
EP1856250A4 (en) NEW LIVING VIRUS VACCINES
EP2128251A4 (en) GENES WITH ENDORED UPDATING FUNDING ACTIVITY